"On Monday, the company announced it would offer both medications, Ozempic (the weight loss version of the drug) and Wegovy (the version that addressed diabetes), at a discounted rate of $199 per month for a limited time. The introductory offer goes from now until March 31, 2026. The announcement noted that the pricing is only good for the first two months of treatment, and at the lowest doses of the medications."
""As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy and Ozempic are affordable and accessible to those who need them," Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc., said in a press release. Moore continued, "The US healthcare system is complex, with different types of insurance and various ways for patients to obtain their medicines. Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay.""
Novo Nordisk is offering Ozempic (the weight loss version of the drug) and Wegovy (the version that addressed diabetes) at reduced self-pay prices. The company will offer the medications for $199 per month for the first two months at the lowest doses as an introductory rate through March 31, 2026. After the initial months the monthly self-pay rate will be $349, down from $499. Novo Nordisk said the offers aim to improve affordability and accessibility for patients without coverage or who choose to self-pay. The offers are available via product websites, NovoCare Pharmacy, and select partners and telehealth providers.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]